Adele K. Fielding
About
In The Last Decade
Adele K. Fielding
134 papers receiving 6.8k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Public Health, Environmental and Occupational Health 3.9k
- Hematology 3.8k
- Oncology 2.2k
- Pediatrics, Perinatology and Child Health 1.3k
- Genetics 1.1k
Countries citing papers authored by Adele K. Fielding
This map shows the geographic impact of Adele K. Fielding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adele K. Fielding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adele K. Fielding more than expected).
Fields of papers citing papers by Adele K. Fielding
This network shows the impact of papers produced by Adele K. Fielding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adele K. Fielding. The network helps show where Adele K. Fielding may publish in the future.
Co-authorship network of co-authors of Adele K. Fielding
This figure shows the co-authorship network connecting the top 25 collaborators of Adele K. Fielding. A scholar is included among the top collaborators of Adele K. Fielding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adele K. Fielding. Adele K. Fielding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 2 | |
| 4 | 36 | |
| 5 | 2 | |
| 6 | 12 | |
| 7 | Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study breakdown → | 298 |
| 8 | 1 | |
| 9 | 13 | |
| 10 | Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → | 291 |
| 11 | 22 | |
| 12 | 15 | |
| 13 | 57 | |
| 14 | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) breakdown → | 537 |
| 15 | Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial breakdown → | 502 |
| 16 | 72 | |
| 17 | 1 | |
| 18 | 190 | |
| 19 | 3 | |
| 20 | 87 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.